drugset / Trial / NCT00147264
Telmisartan-Induced Reduction in Intra-Myocellular Lipids Trial
Phase 3
Completed
120 enrolled
McMaster University
Boehringer Ingelheim · collabCanadian Institutes of Health Research (CIHR) · collabHeart and Stroke Foundation of Canada · collabMedtronic · collab
RandomizedFactorialDouble-blindTreatment
Summary
The purpose of this study is to determine whether telmisartan and/or a low-glycemic index diet are effective in reducing intra-myocellular lipid (muscle fat) content.
Timeline
- Start
- 2004-04
- Primary completion
- 2006-01
- Completion
- 2006-11
Outcome
Missed primary endpoint
paper There was no significant effect of telmisartan in abdominally obese individuals consuming either a low or high glycemic diet, on IMCL content PMID 23731019 ↗
paper Telmisartan increased beta-cell function but did not decrease IMCL or liver fat content or other metabolic parameters among individuals with abdominal obesity. PMID 23731019 ↗
Publications
- Chetty VT, Damjanovic S, Gerstein H, Singh N, Yusuf S, Anand SS, Sharma AM. Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial. Blood Press. 2014 Feb;23(1):54-60. doi: 10.3109/08037051.2013.791411. Epub 2013 Jun 3.
- Kochan AM, Wolever TM, Chetty VT, Anand SS, Gerstein HC, Sharma AM. Glycemic index predicts individual glucose responses after self-selected breakfasts in free-living, abdominally obese adults. J Nutr. 2012 Jan;142(1):27-32. doi: 10.3945/jn.111.146571. Epub 2011 Nov 16.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telmisartan | Other / unclassified | 160 mg | — |